Abstract
At the European conference of the Pistoia Alliance, a global nonprofit, early in 2025, a theme emerged: that agentic artificial intelligence (AI) is viewed by life sciences professionals as potentially being among the most disruptive emerging technologies over the next two to three years (1). Agentic AI has the potential, according to the Pistoia Alliance, to accelerate multi-step processes, such as target prioritization and compound optimization, by joining together reasoning, tool use, and execution.
Key Data
-
Publication Date04 September 2025
-
Primary AuthorPatrick Lavery
-
SourcePharmTech
-
LanguageEnglish
Click below to visit original source: